financetom
Business
financetom
/
Business
/
AAR Q2 Beat Drives Confidence for H2, Overall Aerospace Market, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AAR Q2 Beat Drives Confidence for H2, Overall Aerospace Market, RBC Says
Jan 8, 2025 9:09 AM

11:57 AM EST, 01/08/2025 (MT Newswires) -- AAR's (AIR) fiscal Q2 results exceeded expectations and will support confidence for H2 and the broader aerospace and defense market, RBC Capital Markets said in a note emailed Wednesday.

The parts supply segment was a key growth driver boosted by distribution to US Military, and continued growth in the sector is expected to lead to stronger margins in the fiscal H2, according to the note.

The brokerage is slightly conservative on fiscal 2026 margin outlook, however, margin growth is expected due to synergies from third-party services, expansion in heavy maintenance, repair and overhaul, and continued benefits from the parts supply segment.

"We are more conservative on Integrated System and Repair and Engineering fiscal year 2026 margins relative to our prior estimates," RBC added.

The brokerage maintained an outperform rating for AAR and a $75 price target.

Price: 66.97, Change: +5.22, Percent Change: +8.45

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results
Mar 17, 2025
04:11 AM EDT, 03/17/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Sunday that long-term clinical data from an ongoing phase 1/2 clinical trial of its investigational drug DYNE-251 is showing clinically meaningful and sustained functional improvement in patients with Duchenne muscular dystrophy. The 32-patient trial is specifically for individuals with the rare genetic disease who are amenable to...
Baidu Launches New AI Models
Baidu Launches New AI Models
Mar 17, 2025
04:29 AM EDT, 03/17/2025 (MT Newswires) -- Baidu ( BIDU ) said Sunday it has launched its new artificial intelligence foundational models ERNIE 4.5 and ERNIE X1. ERNIE 4.5 outperforms GPT-4.5 in multiple benchmarks, while the deep-thinking reasoning model ERNIE X1 is capable of performing on par with DeepSeek R1, both at comparatively lower price points, Baidu ( BIDU )...
Foreign-branded smartphone shipments down 21% y/y in China in Jan, CAICT data shows
Foreign-branded smartphone shipments down 21% y/y in China in Jan, CAICT data shows
Mar 17, 2025
BEIJING, March 17 (Reuters) - Shipments of foreign-branded smartphones, including Apple Inc's ( AAPL ) iPhone, in China fell 21% in January year-on-year, according to Reuters' calculations based on data released on Monday by a government-affiliated research firm. Calculations based on the data from the China Academy of Information and Communications Technology (CAICT) showed that during the month shipments of...
Scholar Rock Study of Potential Spinal Muscular Atrophy Treatment Meets Secondary Endpoints
Scholar Rock Study of Potential Spinal Muscular Atrophy Treatment Meets Secondary Endpoints
Mar 17, 2025
04:22 AM EDT, 03/17/2025 (MT Newswires) -- Scholar Rock ( SRRK ) said Sunday that data from a phase 3 trial of its investigational therapy apitegromab showed clinically meaningful and consistent benefits in motor function in patients with spinal muscular atrophy. The trial is for patients already receiving survival motor neuron treatments, the company said. The company said the trial...
Copyright 2023-2026 - www.financetom.com All Rights Reserved